Exhibit 99.1
FOR IMMEDIATE RELEASE
| Contact: | Adam C. Derbyshire | Mike Freeman | ||
| Senior Vice President and | Executive Director, Investor Relations and | |||
| Chief Financial Officer | Corporate Communications | |||
| 919-862-1000 | 919-862-1000 |
SALIX PHARMACEUTICALS TO PRESENT AT
BANK OF AMERICA CONFERENCE
RALEIGH, NC, August 8, 2006 - Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will present at the bank of America 2006 Specialty Pharmaceuticals Conference in Southampton, NY on Friday, August 11 at 12:45 p.m. ET.
Interested parties can access a live audio web cast of these presentations athttp://www.salix.com. A replay of these presentations will be available at the same location.
Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina, develops and markets prescription pharmaceutical products for the treatment of gastrointestinal diseases. Salix’s strategy is to in-license late-stage or marketed proprietary therapeutic drugs, complete any required development and regulatory submission of these products, and market them through the Company’s gastroenterology specialty sales and marketing team. Salix markets COLAZAL®, XIFAXAN®, VISICOL®, OSMOPREP™, MOVIPREP®, AZASAN®, ANUSOL-HC® and PROCTOCORT®. Granulated mesalamine is under development.
Salix trades on the NASDAQ Global Market under the ticker symbol “SLXP”.
For more information please contact the Company at 919-862-1000 or visit our web site atwww.salix.com. Information on our web site is not incorporated in our SEC filings.
